Written Study for Viapro™
Clinical Study
-
Viapro has conducted a randomized, double-blind, placebo-controlled clinical study led by a
-
board-certified urologist on efficacy and safety of Viapro™ (GL49). 47 subjects with mild to
-
moderate erectile dysfunction (ED) were randomized to receive placebo or Viapro™ for one
-
month. Efficacy was assessed by standardized questionnaires and diary after each sexual
-
activity. Safety was assessed by subject report on adverse events and blood tests.
-
The study results show that Viapro™:
-
Significantly increased erectile function (as shown by IIEF (International Index of Erectile
-
Function) EF (Erectile Function) domain score and Question 3 and 4 scores): EF domain score
-
increase of 7.65 with Viapro™ (vs a decrease of 1.74 with placebo, P<0.0001) and significant
-
increase of Question 3 (ability to obtain an erection) and Question 4 (ability to maintain an
-
erection) scores (P<0.0001)
-
Significantly increased firmness and duration of erections: over 91% of subjects were able to
-
penetrate successfully; over 85% of subjects were able to complete intercourse successfully;
-
83% had increased firmness of erections; 75% had increased duration of erections
-
Made clinically significant improvement on 80% of subjects with ED (defined as EF
-
increase>=5) (P<0.0001 vs placebo)
-
Helped 62.5% of subjects with erectile dysfunction (ED) regain normal sexual function
-
(clinically defined as EF>=26) after taking Viapro™ for one month (P<0.0001 vs placebo)
-
Significantly increased sexual desire in subjects with regular or low sex drive: IIEF Sexual
-
Desire domain score increase of 1.46 with Viapro™ (vs a decrease of 0.46 with placebo,
-
P<0.0001); more than 70% of subjects reported increase in sex drive and intercourse frequency
-
with Viapro™ (vs 13.04% and 8.7% with placebo, respectively, P<0.0001); 71% of subject
-
with self-reported low sex drive had significant increase in sexual desire with Viapro™ (vs 0%
-
with placebo)
-
Lasted 24-48 hours with one dose
-
Significantly improved sexual relationship, self confidence and quality of life: IIEF Overall
-
Satisfaction domain score increase of 2.00 with Viapro™ (vs a decrease of 0.39 with placebo,
-
P<0.0001); more than 75% of subjects reported improvement in sex life; 67% reported
-
improvement in sexual relationship; 79% reported improvement in confidence of sexual ability;
-
79% reported improvement in self-esteem; 75% reported improvement in quality of life; 75% of
-
subjects and partners reported feeling happier after the study
-
Showed no serious side effects: only mild and temporary side effects were reported by a small
-
percentage of subjects
-
These results suggest that Viapro™ may be effective and safe for improving male erectile
-
function and sexual desire. |
